Ermany Expand Clinical Collaboration To Include Phasei Iia Trial Investigating The Combination Of Snk01 With Erbitux Cetuximab In Metastatic Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 13, 2021
SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) NKMax, a biotechnology company harnessing the power of the body s immune system through the development of Natural Killer (NK) cell therapies, announced the expansion of its clinical trial and supply agreement with Merck KGaA, Darmstadt, Germany to conduct a Phase I/IIa open-label, single-center trial evaluating the safety and anti-tumor activity of SNK01 (autologous natural killer cells) in combination with either gemcitabine/carboplatin or gemcitabine/carboplatin plus cetuximab (ERBITUX®) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after prior tyrosine kinase inhibitor (TKI) therapy. Preliminary ....

Soult Ukpyolsi , South Korea , United States , Kyonggi Do , Jae Cheol Lee , Denise Chua , Nkmax Co , Merck Kga , Merck Kgaa , Department Of Oncology , Lung Cancer Center At Asan Medical , Natural Killer , Lung Cancer Center , Asan Medical Center , Dasan Hospital , Sangwoo Park , Chief Executive Officer , Seongnam South Korea , Santa Ana , Kmax And Merck Kgaa , Ermany Expand Clinical Collaboration To Include Phasei Iia Trial Investigating The Combination Of Snk01 With Erbitux Cetuximab In Metastatic Nsclc , தெற்கு கொரியா , ஒன்றுபட்டது மாநிலங்களில் , மறுக்க சுய , மெர்க் க்க , துறை ஆஃப் புற்றுநோயியல் ,